Regulatory PathRegulatory requirements compared

Active substance

Dermatophagoides pteronyssinus

Open in the medicines table

Canada Canada — marketed products (Health Canada)

BrandDINStrengthForm · routeCompany
ALLERGENIC EXTRACT - STANDARDIZED MITE DERMATOPHAGOIDES PTERONYSSINUS0223132410000 UNIT / MLLIQUID · SUBCUTANEOUS; INTRACUTANEOUSGREER LABORATORIES INC
ALLERGENIC EXTRACT STANDARDIZED MITE DP (10,000 AU/ML)0222393710000 UNIT / MLSOLUTION · PERCUTANEOUS; SUBCUTANEOUSJUBILANT HOLLISTERSTIER LLC
ALLERGENIC EXTRACT STANDARDIZED MITE DP (30,000 AU/ML)0222394530000 UNIT / MLSOLUTION · PERCUTANEOUS; SUBCUTANEOUSJUBILANT HOLLISTERSTIER LLC
ALLERGENIC EXTRACT, STANDARDIZED MITE, D.PTERONYSSINUS0221710410000 UNIT / MLLIQUID · INTRADERMAL; PERCUTANEOUS; SUBCUTANEOUSALK-ABELLO INC

UK MHRA United Kingdom — marketing authorisations

ProductAuthorisationHolderLegal status
D. PTERONYSSINUS 10,000 DU/ML ODCPL 17087/0018ALLERGY THERAPEUTICS (UK) LIMITEDPOM
SOLUPRICK SQ DERMATOPHAGOIDES PTERONYSSINUS 10 HEPPL 10085/0047ALK ABELLO A-SPOM

Combinations containing Dermatophagoides pteronyssinus

Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), MHRA category lists of UK marketing authorisations (Open Government Licence v3.0), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.